CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia

References

• Burger JA, O’Brien S. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510–527.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011;117(6):1781–1791.
   PubMed Web of Science ®Google Scholar
• Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183–2198.
   PubMed Web of Science ®Google Scholar
• Parikh SA, Strati P, Tsang M, et al. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127(14):1752–1760.
   PubMed Web of Science ®Google Scholar
• The International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790.
   PubMed Web of Science ®Google Scholar
• Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375–380.
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Swinnen L, Kasamon Y, et al. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52(10):1873–1881.
   PubMed Web of Science ®Google Scholar
• Gladstone DE, Blackford A, Cho E, et al. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012;12(2):132–137.
   PubMed Web of Science ®Google Scholar
• Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo clinic experience. Blood. 2009;114(5):957–964.
   PubMed Web of Science ®Google Scholar
• Van Dyke DL, Werner L, Rassenti LZ, et al. The dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL research consortium experience. Br J Haematol. 2016;173(1):105–113.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Ishikawa F, Toshihiro Miyamoto T, et al. Self-Renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2):246–259.
   PubMed Web of Science ®Google Scholar
• Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4(9):1088–1101.
   PubMed Web of Science ®Google Scholar
• Di Ianni M, Baldoni S, Del Papa B, et al. NOTCH1 is aberrantly activated in chronic lymphocytic leukemia hematopoietic stem cells. Front Oncol. 2018;8:105.
   PubMed Web of Science ®Google Scholar
• Quijada-Álamo M, Hernández-Sánchez M, Robledo C, et al. Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. J Hematol Oncol. 2017;10(1):83.
   PubMedGoogle Scholar
• Sharrow AC, Ghiaur G, Jones RJ. Cancer stem cell principles. In: Bast RC, Markman M, Hawk E, Tsimberidou A-M, Kurzrock R, Anderson KC, editors. Targeted therapy in translational cancer research. John Wiley & Sons, Inc.; 2015. pp 39–46.
   Google Scholar
• Zeisberger SM, Odermatt B, Marty C, et al A. H. et al. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer. 2006;95(3):272–281.
   PubMed Web of Science ®Google Scholar
• Bender JG, Unverzagt KL, Walker DE, et al. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood. 1991;77(12):2591–2596.
   PubMed Web of Science ®Google Scholar
• Berger M, Rapatel C, Boiret N, et al. Peripheral progenitor cells (CFU-GM, BFU-E, CD34) are increased in untreated chronic lymphocyte leukemia patients: stage B and C display a particularly high CD34+ cell count. Leuk Lymphoma. 1999;35(5–6):587–591.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Wiestner A. Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. Semin Oncol. 2016;43(2):222–232.
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92(1):97–103.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441–4450.
   PubMed Web of Science ®Google Scholar
• Mongini PK, Gupta R, Boyle E, et al. TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells. JI. 2015;195(3):901–923.
   Google Scholar
• Dürig J, Ebeling P, Grabellus F, et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res. 2007;67(18):8653–8661.
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambello R, Agostini C, et al. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood. 1994;84(12):4249–4256.
   PubMed Web of Science ®Google Scholar
• Palacios R, Henson G, Steinmetz M, et al. Interleukin-3 supports growth of mouse pre-B-cell clones in vitro. Nature. 1984;309(5964):126–131.
   PubMed Web of Science ®Google Scholar
• Palacios R, Steinmetz M. IL-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. 1985;41(3):727–734.
   PubMed Web of Science ®Google Scholar
• Tadmori W, Feingersh D, Clark SC, et al. Human recombinant IL-3 stimulates B cell differentiation. J Immunol. 1989;142(6):1950–1955.
   PubMed Web of Science ®Google Scholar
• Sevilla DW, Colovai AI, Emmons FN, et al. Hematogones: a review and update. Leuk Lymphoma. 2010;51(1):10–19.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Jones RJ. Acute myeloid leukemia stem cell heterogeneity and its clinical relevance. Vol. 1139. In: Birbrair A, editor. Advances in Experimental Medicine and Biology. Springer New York LLC; 2019. p. 153–169.
   Google Scholar
• Yun S, Zhang L, Patel MR, et al. Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia. Blood. 2018;131(11):1258–1261.
   PubMed Web of Science ®Google Scholar
• Johnsen HE, Bergkvist KS, Schmitz A, Myeloma Stem Cell Network (MSCNET), et al. Myeloma stem cell network (MSCNET). cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy. Leuk Lymphoma. 2014;55(6):1251–1260.
   PubMed Web of Science ®Google Scholar